Pfizer Inc. (PFE)
Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note
Pfizer (PFE) reachead $28.93 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.
1 Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist and 1 to Avoid
Income investors have both good and not-so-good options in the healthcare sector.
Pfizer: Activists Clouding A Promising Picture
Pfizer's deep valuation and large dividend yield make it an attractive investment, despite potential distractions from activist investors. The focus should remain on existing cost realignment plans and pipeline investments to ensure positive financial returns for shareholders. The stock only trades at 10x forward EPS targets.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Why I'm Considering Leaning Heavily Into Pfizer
Pfizer's high dividend yield and robust pipeline could offer significant returns for patient investors.
How to play biotech stocks: Johnson & Johnson, Pfizer
Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie Hyman and Josh Lipton to break down how to play biotech and pharmaceutical stocks. Johnson & Johnson reports earnings on Tuesday, which Shibutani says “typically kicks off earnings season for healthcare, but also for the large-cap pharmas.
Pfizer taps Vanguard veteran for board amid fight with Starboard
Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as it faces pressure from activist hedge fund Starboard Value.
Pfizer Is Clashing With Its New Activist Investor. Will It Harm The Stock?
This investor's campaign is stoking some undesirable corporate intrigue.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Pfizer (PFE) stood at $29.08, denoting a -0.27% change from the preceding trading day.
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
These two stocks will appeal to very different types of investors at the moment.
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for constant intravenous infusions or injections, which are painful as well as inconvenient.
